Navigation Links
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/14/2008

BOULDER, Colo. and MONTREAL, Feb. 14 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of acute myelogenous leukemia (AML) in the United States. Criteria for designation require that the product be intended for treatment of a condition affecting fewer than 200,000 people in the United States, and the application must include a rationale for the use of the drug in the rare disease or condition.

Orphan Drug Designation allows special incentives for sponsors planning to test a product for use in a rare disease or condition. These incentives include, tax credits, research and development grant funding, and reduced filing fees at the time of application for marketing approval. Once approved, the product may qualify for seven years of marketing exclusivity in the United States.

About MGCD0103

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in one Phase I combination clinical trial with Taxotere(R) for solid tumors, two Phase I/II combination trials with Vidaza(R) for hematological malignancies and with Gemzar(R) for pancreatic cancer, and five Phase II clinical trials in hematological malignancies.

MGCD0103 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and has been designated an Orphan Medicinal Product by the EMEA for the treatment of Hodgkin lymphoma and acute myelogenous leukemia.

About Acute Myelogenous Leukemia (AML)

Acute myelogenous leukemia (AML) is a cancer of the blood and bone marrow that
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
4. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
7. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
8. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
9. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
10. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
11. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 BGI announced today ... Hong Kong has been accredited by the ... is the first clinical next-generation-sequencing laboratory to receive the ... the highest standard in clinical laboratory practices. Complementary to the ... laboratory process, and multiple ISO certifications, the CAP certification ...
(Date:7/1/2015)... Ill. , July 1, 2015 ... nationwide group of state and regional professional rheumatology ... survey of rheumatologists that explored perceptions of biosimilars ... on patients. Biosimilars are medicines ... biologic medicines. They are notably different from generic ...
(Date:7/1/2015)... -- Eli Lilly and Company (NYSE: LLY ) will ... on Thursday, July 23, 2015. Lilly will also conduct a ... media to further detail the company,s financial performance. ... media and the general public can access a live webcast ... posted on Lilly,s website at www.lilly.com . A replay ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2
(Date:7/2/2015)... ... July 02, 2015 , ... The ZAC Foundation, a ... swim season with important lessons on how to stay water safe with the help ... Wouldn’t Swim, authored by The ZAC Foundation co-founders, follows Zeke’s water safety journey. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... today that it has reached an agreement to acquire eRubbermaid.com, an Internet ... distributor of Rubbermaid Commercial Products on the web today. , ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... Research (CVR) recently received nearly $4 million through five federal grants to ... vaccines and therapies against the deadly diseases. , The research will be ...
(Date:7/2/2015)... ... July 02, 2015 , ... B. E. ... been retained to lead a national chief operating officer recruitment for ... in the healthcare industry, B. E. Smith has recently placed more than 1,000 ...
(Date:7/2/2015)... ... 2015 , ... Evolved Ayurvedic Discoveries , Inc. (EAD ... to partner with companies that share a similar mission of providing the most ... Cannabidiol (CBD) formulations, combined with Ayurvedic herbs, are now available for wholesale, private ...
Breaking Medicine News(10 mins):Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:CleanItSupply.com Acquires eRubbermaid.com 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3
... The Lorillard Tobacco,Company today issued the following statement ... House Committee on Energy and Commerce that would force ... tobacco industry., "The Lorillard Tobacco Company opposes H.R. ... tobacco. While Lorillard fully supports,reasonable federal regulation of the ...
... Mobility Helps Courageous Texas Man Fight Illness and Enjoy ... Last,December, James Matthijetz was in the process of ... could fully celebrate, the,24-year-old felt his body stiffen while ... had a brain hemorrhage and a minor stroke from ...
... April 4, 2008 The Pacific,Heart, Lung & ... products and adequate funding for research on,asbestos-related diseases. ... currently referred to as the "committee print," is ... provide meaningful funding., Public health concerns should ...
... with 2008 National Public Health Week, April,7-13, ... J. Markey (D-Mass.) and Congresswoman Hilda L. Solis,(D-Calif.) ... and Global,Warming on today,s introduction of a resolution ... relationship between public health,and global warming., The ...
... Personal interventions cut no-show rates 30%, study finds ... new studies make the case that more personal ... of low-income and minority patients getting recommended screening ... current issue of Clinical Gastroenterology and Hepatology ...
... Global Action Board of Directors brings ,hands on, approach ... direction to achieving Global Action,s mission statement, BOSTON, ... Global,Action announces today the recent addition of Robert Hernreich ... of Edwards,Colorado and Las Vegas, Nevada officially took his ...
Cached Medicine News:Health News:The SCOOTER Store Donates Power Scooter to an Uninsured Young Father Battling Cancer 2Health News:The SCOOTER Store Donates Power Scooter to an Uninsured Young Father Battling Cancer 3Health News:Pacific Heart, Lung & Blood Institute Position on Ban Asbestos Legislation 2Health News:Pacific Heart, Lung & Blood Institute Position on Ban Asbestos Legislation 3Health News:Patient Navigators Boost Colon Screens in Urban Minorities 2Health News:Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich 2
... provides fingertip ratchet disengagement allowing smooth, ratchet-free ... offers state-of-the-art quality in an instrument of ... durability. Low profile cutting tips allow access ... I instruments are available in just about ...
... The patented ratchet design provides fingertip ... ,The Series I Instrument program offers state-of-the-art ... profile, while maintaining strength and durability. Low ... in tight joint spaces. Series I instruments ...
... The patented ratchet design provides fingertip ratchet ... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ...
... A broad selection of procedurally specific ... and allow easy access to all ... variety of approaches.,Loop Handled Graspers feature ... holds tissue firmly without tearing or ...
Medicine Products: